Fecal microbiome composition at baseline predicted semaglutide treatment response, enabling potential microbiome-based pre-treatment patient selection for GLP-1 therapy.
Bacteria predict drug responseTesting gut bacteria BEFORE starting semaglutide could predict who will respond — personalized medicine through microbiome analysis
What the researchers found
Baseline fecal microbiome composition predicted semaglutide treatment response, with specific bacterial signatures distinguishing responders from non-responders before treatment initiation.
Why it matters
Predicting GLP-1 drug response before treatment saves time, money, and patient suffering from trial-and-error prescribing.
How the study worked
Fecal microbiome analysis (16S/metagenomic) at baseline and during semaglutide treatment, with correlation to treatment outcomes.
What this study cannot tell us
Specific predictive accuracy metrics in full paper. Validation in independent cohorts needed.
How to read the evidence
Predictive microbiome study. Novel finding needing validation.
When this study was published
Published in 2025.
The bigger picture
Microbiome-guided prescribing represents the next frontier of precision medicine for GLP-1 therapy.
Questions still open
- Could microbiome testing become standard before GLP-1 prescribing?
- Would prebiotic/probiotic optimization improve semaglutide response?
- Which specific bacterial species predict response?
Common questions
Could a stool test predict if Ozempic will work for me?
Can I change my microbiome to respond better?
Read the original research
Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.
Scientific reports, 16(1), 6126
Citation
Klemets, Annabel; Reppo, Ingrid; Krigul, Kertu Liis; Volke, Vallo; Aasmets, Oliver; Org, Elin. (2026). Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.. Scientific reports, 16(1), 6126. https://doi.org/10.1038/s41598-026-36318-3